{
    "clinical_study": {
        "@rank": "57034", 
        "acronym": "OPEN", 
        "arm_group": {
            "arm_group_label": "Optiflow", 
            "arm_group_type": "Experimental", 
            "description": "The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access."
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the performance and safety of the Optiflow\n      Anastomotic Connector (Optiflow) when used to facilitate the creation of autogenous\n      arteriovenous fistula (AVF) anastomoses."
        }, 
        "brief_title": "The Optiflow Patency and Maturation Study", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "End-stage Kidney Disease", 
            "End-stage Renal Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigation is designed as a multi-center, prospective, single-arm, clinical study of\n      the Optiflow performance and safety in a maximum of 170 subjects which includes two (2)\n      roll-in subjects per investigator (maximum of 36 roll-in subjects).  Subjects will be\n      followed at 14 days post-procedure, 42 days post-procedure, and 90 days post-procedures.\n\n      Results will be compared to a pre-established performance goal.\n\n      Up to ten (10) investigational sites will participate in the investigational study.\n\n      The primary performance endpoint is the overall maturation percentage rate at 90 days.\n      Maturation is defined as an access site which achieves a diameter of greater or equal to 4\n      mm and blood flow greater or equal t0 500 mL/min as measured via duplex ultrasound.\n\n      The primary safety endpoint is a composite endpoint of serious adverse events known to be\n      associated with arteriovenous fistula anastomosis surgical procedures through 90 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or non-pregnant female (verified with a urine/blood pregnancy test, for women of\n             reproductive age).\n\n          -  Life expectancy of at least one year, per the investigator's opinion.\n\n          -  Diagnosed with ESRD or chronic kidney disease requiring dialysis or anticipated start\n             of dialysis within six months of enrollment.\n\n          -  Planned upper extremity autogenous arteriovenous fistula.\n\n          -  Planned anastomosis is an end of vein to side of artery configuration.\n\n          -  AVF target artery and vein inner diameters are greater or equal to 3.0 mm and less\n             than or equal to 7.0 mm as determined by pre-operative ultrasound and confirmed\n             intra-operatively.\n\n          -  Patient is available and willing to return for follow-up visits during the duration\n             of the study.\n\n          -  Patient is able and willing to follow a daily aspirin and/or other\n             anticoagulation/antiplatelet regimen not including warfarin (see exclusion criteria).\n\n          -  Patient, or their legal representative, is willing and able to provide informed\n             consent.\n\n        Exclusion Criteria:\n\n          -  Known bleeding diathesis or coagulation disorder.\n\n          -  Documented or suspected central venous stenosis.\n\n          -  Uncontrolled hypotension with systolic blood pressures < 100 mg Hg at the time of\n             screening.\n\n          -  Peripheral white blood cell count < 1.5 K/mm3 or platelet count < 75,000 cells/mm3.\n\n          -  Body Mass Index (BMI) > 42.\n\n          -  Transposition of the access vein is anticipated within the 90 day follow-up interval.\n\n          -  Receiving therapeutic warfarin therapy.\n\n          -  Evidence or history of an active or suspected infection within one month of\n             screening.\n\n          -  Scheduled kidney transplant within six months of enrollment.\n\n          -  History of \u2265 2 AVF and/or synthetic access graft failures.\n\n          -  History of steal syndrome from a previous hemodialysis vascular access which required\n             intervention or abandonment.\n\n          -  Current participation in another clinical trial (excluding retrospective studies or\n             studies not requiring a consent form).\n\n          -  Anticipated surgery requiring general anesthesia during the course of follow-up.\n\n          -  A history of substance abuse.\n\n          -  Anticipated to be non-compliant with medical care or study requirements based on\n             investigator judgment.\n\n          -  Need for immunosuppressive therapy at a dose greater than the equivalent of\n             prednisone 10 mg per day."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921933", 
            "org_study_id": "BCS_TP1070"
        }, 
        "intervention": {
            "arm_group_label": "Optiflow", 
            "description": "The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.", 
            "intervention_name": "Optiflow", 
            "intervention_type": "Device", 
            "other_name": "Optiflow Anastomotic Connector"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "End-stage renal disease", 
            "ESRD", 
            "AVF", 
            "Fistulas"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "contact": {
                "email": "ROYCHAP@UCMAIL.UC.EDU", 
                "last_name": "Prabir Roy-Chaudhury, MD, PhD", 
                "phone": "513-558-4006"
            }, 
            "contact_backup": {
                "email": "cannant@ucmail.edu", 
                "last_name": "Tamar Canaan, RN, NSN", 
                "phone": "513-558-7438"
            }, 
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45267-0585"
                }, 
                "name": "University of Cincinnati - Division of Nephrology"
            }, 
            "investigator": {
                "last_name": "Prabir Roy-Chaudhury, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "The \"OPEN\" Study Optiflow PatEncy and MaturatioN", 
        "other_outcome": [
            {
                "description": "Elapsed time to first use of access site.", 
                "measure": "Time to first cannulation", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "description": "Flow rate of blood through outflow vein", 
                "measure": "Ultrasound flow", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Elapsed time to abandonment of the access site.", 
                "measure": "Time To Access Site Abandonment", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "description": "The number of access related adverse events per subject", 
                "measure": "Access Site Related Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "description": "The number of access site related hospitalizations per subject.", 
                "measure": "Number of Access Site Related Hospitalizations", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Total number of days a catheter was used before access site maturation per subject.", 
                "measure": "Catheter Utilization", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Total number of adverse events", 
                "measure": "Total Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary performance endpoint is the maturation percentage rate at 90 days.  Maturation is defined as an access site intended for dialysis needle cannulation which achieves a diameter of greater or equal to 4 mm and blood flow greater or equal to 500 mL/min as measured via duplex ultrasound.", 
                "measure": "Fistula Maturation", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "The primary safety endpoint is a composite endpoint of serious adverse events known to be associated with arteriovenous fistula anastomosis surgical procedures through 90 days.  All patients will be followed for safety for the duration of the study.", 
                "measure": "Serious Adverse Events Associated with Arteriovenous Fistula Creation", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921933"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Technical success rate: An access site that demonstrates physical exam patency through hospital discharge.", 
                "measure": "Technical success", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "Assisted maturation rate: An access site which achieves or maintains maturation following intervening manipulations (surgical or endovascular) designed to promote or reestablish maturation.", 
                "measure": "Assisted Maturation", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Unassisted fistula maturation rate: An access site that achieves and maintains maturation without any surgical or endovascular intervention designed to promote or reestablish Maturation.", 
                "measure": "Unassisted Maturation", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Assisted patency rate: An access site which is patent after intervening manipulations (surgical or endovascular) intended to promote or reestablish patency.", 
                "measure": "Assisted Patency", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Unassisted patency rate: An access site that maintains patency without any surgical or endovascular intervention designed to maintain or reestablish blood flow in the access site.", 
                "measure": "Unassisted Patency", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Intervention rate: The number of occurrences that a subject's access site is surgically or endovascularly operated on to maintain or reestablish blood flow in the access site.", 
                "measure": "Intervention Rate", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }
        ], 
        "source": "Bioconnect Systems, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bioconnect Systems, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}